ASX - By Stock
|
MSB |
Re:
Mesoblast stock(rock)-take March 2024
|
|
pld89
|
272 |
111K |
3 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
272
|
111K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
CLBP Trial 2024
|
|
pld89
|
6 |
2.3K |
4 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
6
|
2.3K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast stock(rock)-take March 2024
|
|
pld89
|
272 |
111K |
4 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
272
|
111K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast stock(rock)-take March 2024
|
|
pld89
|
272 |
111K |
11 |
15/04/24 |
15/04/24 |
ASX - By Stock
|
272
|
111K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
MSB shareholder class action
|
|
pld89
|
116 |
41K |
3 |
15/04/24 |
15/04/24 |
ASX - By Stock
|
116
|
41K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
pld89
|
567 |
211K |
14 |
14/04/24 |
14/04/24 |
ASX - By Stock
|
567
|
211K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
pld89
|
549 |
170K |
8 |
13/04/24 |
13/04/24 |
ASX - By Stock
|
549
|
170K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
pld89
|
9.5K |
2.7M |
1 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
9.5K
|
2.7M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast stock(rock)-take March 2024
|
|
pld89
|
272 |
111K |
0 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
272
|
111K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
pld89
|
133 |
44K |
2 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
133
|
44K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
pld89
|
9.5K |
2.7M |
1 |
07/04/24 |
07/04/24 |
ASX - By Stock
|
9.5K
|
2.7M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
pld89
|
567 |
211K |
6 |
06/04/24 |
06/04/24 |
ASX - By Stock
|
567
|
211K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
MSB Class Action
|
|
pld89
|
218 |
67K |
6 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
218
|
67K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Upcoming Newsflow & Re-rate Estimations
|
|
pld89
|
52 |
23K |
3 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
52
|
23K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
MSB shareholder class action
|
|
pld89
|
116 |
41K |
2 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
116
|
41K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
MSB shareholder class action
|
|
pld89
|
116 |
41K |
0 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
116
|
41K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
MSB shareholder class action
|
|
pld89
|
116 |
41K |
11 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
116
|
41K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
pld89
|
551 |
197K |
7 |
31/03/24 |
31/03/24 |
ASX - By Stock
|
551
|
197K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
pld89
|
551 |
197K |
21 |
31/03/24 |
31/03/24 |
ASX - By Stock
|
551
|
197K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast stock(rock)-take March 2024
|
|
pld89
|
272 |
111K |
10 |
30/03/24 |
30/03/24 |
ASX - By Stock
|
272
|
111K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
pld89
|
567 |
211K |
5 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
567
|
211K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
pld89
|
551 |
197K |
3 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
551
|
197K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
pld89
|
551 |
197K |
6 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
551
|
197K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
pld89
|
567 |
211K |
7 |
24/03/24 |
24/03/24 |
ASX - By Stock
|
567
|
211K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
pld89
|
567 |
211K |
3 |
24/03/24 |
24/03/24 |
ASX - By Stock
|
567
|
211K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
pld89
|
17K |
6.6M |
5 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
17K
|
6.6M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
pld89
|
549 |
170K |
11 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
549
|
170K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
pld89
|
549 |
170K |
25 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
549
|
170K
|
25
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
pld89
|
549 |
170K |
12 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
549
|
170K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
MSB Charts
|
|
pld89
|
83 |
38K |
1 |
17/03/24 |
17/03/24 |
ASX - By Stock
|
83
|
38K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
pld89
|
549 |
170K |
10 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
549
|
170K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
pld89
|
549 |
170K |
9 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
549
|
170K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
pld89
|
567 |
211K |
14 |
10/03/24 |
10/03/24 |
ASX - By Stock
|
567
|
211K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
pld89
|
567 |
211K |
10 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
567
|
211K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
pld89
|
9.5K |
2.7M |
5 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
9.5K
|
2.7M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
pld89
|
567 |
211K |
2 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
567
|
211K
|
2
|
|
ASX - By Stock
|
EIQ |
Re:
Ann: Half Year Accounts 31 December 2023
|
|
pld89
|
2 |
791 |
1 |
04/03/24 |
04/03/24 |
ASX - By Stock
|
2
|
791
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast Shareholder Class Action (VID268/2022) – Notice to Group Members
|
|
pld89
|
168 |
96K |
40 |
04/03/24 |
04/03/24 |
ASX - By Stock
|
168
|
96K
|
40
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Half Year Report and Accounts (including Appendix 4D)
|
|
pld89
|
31 |
9.3K |
5 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
31
|
9.3K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Orphan Drug Designation for Revascor
|
|
pld89
|
272 |
98K |
2 |
24/02/24 |
24/02/24 |
ASX - By Stock
|
272
|
98K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
pld89
|
9.5K |
2.7M |
4 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
9.5K
|
2.7M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
pld89
|
17K |
6.6M |
4 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
17K
|
6.6M
|
4
|
|
ASX - By Stock
|
EIQ |
Re:
Ann: EIQ Licenses Software to Respiri - Remote Patient Monitoring
|
|
pld89
|
13 |
5.4K |
0 |
20/02/24 |
20/02/24 |
ASX - By Stock
|
13
|
5.4K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Orphan Drug Designation for Revascor
|
|
pld89
|
272 |
98K |
2 |
18/02/24 |
18/02/24 |
ASX - By Stock
|
272
|
98K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Orphan Drug Designation for Revascor
|
|
pld89
|
272 |
98K |
4 |
17/02/24 |
17/02/24 |
ASX - By Stock
|
272
|
98K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Orphan Drug Designation for Revascor
|
|
pld89
|
272 |
98K |
4 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
272
|
98K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
pld89
|
9.5K |
2.7M |
8 |
09/02/24 |
09/02/24 |
ASX - By Stock
|
9.5K
|
2.7M
|
8
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
pld89
|
9.5K |
2.7M |
6 |
09/02/24 |
09/02/24 |
ASX - By Stock
|
9.5K
|
2.7M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
pld89
|
9.5K |
2.7M |
0 |
07/02/24 |
07/02/24 |
ASX - By Stock
|
9.5K
|
2.7M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
pld89
|
102 |
37K |
0 |
05/02/24 |
05/02/24 |
ASX - By Stock
|
102
|
37K
|
0
|
|